ConductScience.org, home

Paper42477293

CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.

Ellyan NS and 4 others. Clin Exp Med, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies. Papers, record 42477293. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42477293

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.
PubMed
Journal
Clin Exp Med
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-29
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ellyan NSNavas Shereef
2Alex ATAngel Treasa
3Nayak UYUsha Yogendra
4Raj AAlan
5K RRahulhttps://orcid.org/0000-0003-3116-9610

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Triple Negative Breast NeoplasmsMajor topic
Casein Kinase IIMajor topic
Signal TransductionMajor topic
Protein Kinase InhibitorsMajor topic
Antineoplastic AgentsMajor topic
Humans
Female
Animals
Epithelial-Mesenchymal Transition

Source PubMed

Download CSV of topics

References122

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131443516Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.Cells2019https://conductscience.org/library/papers/31443516PubMed
232218358Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.Molecules2020https://conductscience.org/library/papers/32218358PubMed
315818404Protein kinase CK2 phosphorylates and upregulates Akt/PKB.Cell Death Differ2005https://conductscience.org/library/papers/15818404PubMed
432088086Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets.Pathol Res Pract2020https://conductscience.org/library/papers/32088086PubMed
522317921Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7.Sci Signal2012https://conductscience.org/library/papers/22317921PubMed
625916826SHP2: a new target for pro-senescence cancer therapies.EMBO J2015https://conductscience.org/library/papers/25916826PubMed
724051329Requirement of B-Raf, C-Raf, and A-Raf for the growth and survival of mouse embryonic stem cells.Exp Cell Res2013https://conductscience.org/library/papers/24051329PubMed
830052635CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer.PLoS Biol2018https://conductscience.org/library/papers/30052635PubMed
929228705YAP1 inhibition radiosensitizes triple negative breast cancer cells by targeting the DNA damage response and cell survival pathways.Oncotarget2017https://conductscience.org/library/papers/29228705PubMed
1035018117The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.Cancer Manag Res2022https://conductscience.org/library/papers/35018117PubMed
1112948524The CC chemokine CCL20 and its receptor CCR6.Cytokine Growth Factor Rev2003https://conductscience.org/library/papers/12948524PubMed
1236813121Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer.Biochem Pharmacol2023https://conductscience.org/library/papers/36813121PubMed
1339880265Functional epitope mapping of cell surface glucose-regulated protein 94: A combinatorial approach for therapeutic targeting.Int J Biol Macromol2025https://conductscience.org/library/papers/39880265PubMed
1439827153CK2α-mediated phosphorylation of DUB3 promotes YAP1 stability and oncogenic functions.Cell Death Dis2025https://conductscience.org/library/papers/39827153PubMed
1526735014Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.Nature2016https://conductscience.org/library/papers/26735014PubMed
1622079671GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum.Biochim Biophys Acta2012https://conductscience.org/library/papers/22079671PubMed
1730683840CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.Cell Death Dis2019https://conductscience.org/library/papers/30683840PubMed
1831583500Protein kinase CK2 is involved in zinc homeostasis in breast and prostate cancer cells.Biometals2019https://conductscience.org/library/papers/31583500PubMed
1936499487Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression.Int J Mol Sci2022https://conductscience.org/library/papers/36499487PubMed
2029807221MRTF-A mediates the activation of COL1A1 expression stimulated by multiple signaling pathways in human breast cancer cells.Biomed Pharmacother2018https://conductscience.org/library/papers/29807221PubMed

See all 122 referencesDownload CSV of references

Genes5

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
COL11A21302PubTator's text mininghttps://conductscience.org/library/genes/1302NCBI Gene
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
PIK3CB5291PubTator's text mininghttps://conductscience.org/library/genes/5291NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42477293

GET https://conductscience.org/api/papers/v1/42477293/references?page=2